aTyr Pharma aligns with FDA on Phase 3 efzofitimod trial in pulmonary sarcoidosis

aTyr Pharma aligned with the FDA on a Phase 3 efzofitimod trial in chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. Study-related activities are expected to start in Q4 2026 as the company prepares U.S. and European regulatory submissions. Trial will test whether efzofitimod can improve lung function and patient-reported symptoms versus placebo in a global, randomized, double-blind design. Support comes from a previously presented subgroup analysis showing clinically meaningful benefit in the targeted restrictive-lung subgroup. Future development is expected to require additional funding, including potential equity or debt financing or partnering. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via (Ref. ID: 202609240600PRIMZONEFULLFEED9833031) on September 24, 2026, and is solely responsible for the information contained